Cobimetinib

Generic Name
Cobimetinib
Brand Names
Cotellic
Drug Type
Small Molecule
Chemical Formula
C21H21F3IN3O2
CAS Number
934660-93-2
Unique Ingredient Identifier
ER29L26N1X
Background

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metasta...

Indication

Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.

Associated Conditions
Histiocytic Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Associated Therapies
-
Clinical Trials
Related News

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

First Posted Date
2018-06-12
Last Posted Date
2024-11-21
Lead Sponsor
Mayo Clinic
Target Recruit Count
59
Registration Number
NCT03554083
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

First Posted Date
2018-04-13
Last Posted Date
2024-06-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
528
Registration Number
NCT03498521
Locations
🇦🇺

Northern Cancer Institute, St Leonards, New South Wales, Australia

🇦🇺

Blacktown Hospital, Blacktown, New South Wales, Australia

🇫🇮

Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland

and more 134 locations

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

First Posted Date
2018-02-13
Last Posted Date
2023-09-14
Lead Sponsor
Technische Universität Dresden
Target Recruit Count
20
Registration Number
NCT03430947
Locations
🇩🇪

Technische Universität Dresden, Dresden, Germany

🇩🇪

Ruprecht-Karls-University of Heidelberg, Faculty of Medicine, Heidelberg, Germany

🇩🇪

Eberhard Karls University of Tübingen, University Medical Center, Tuebingen, Germany

Pre-operative Immunotherapy Combination Strategies in Breast Cancer

First Posted Date
2018-01-10
Last Posted Date
2024-06-18
Lead Sponsor
Queen Mary University of London
Target Recruit Count
71
Registration Number
NCT03395899
Locations
🇬🇧

Barts Health NHS Trust, London, United Kingdom

BEACON - ABC in Recurrent Platinum Resistant HGSOC

First Posted Date
2017-12-06
Last Posted Date
2023-08-07
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Target Recruit Count
30
Registration Number
NCT03363867
Locations
🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer

First Posted Date
2017-11-13
Last Posted Date
2018-10-09
Lead Sponsor
Niharika Mettu
Registration Number
NCT03340558
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

First Posted Date
2017-11-09
Last Posted Date
2024-06-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
675
Registration Number
NCT03337698
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei City, Taiwan

🇪🇸

Hospital Clinico Universitario de Valencia, Valencia, Spain

🇨🇳

National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan

and more 33 locations

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

First Posted Date
2017-10-17
Last Posted Date
2023-02-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
49
Registration Number
NCT03312530
Locations
🇫🇷

CHU - Hôtel Dieu hematolgie clinique, Nantes, France

🇨🇿

Fakultni nemocnice Ostrava; Klinika hematoonkologie, Ostrava, Czechia

🇨🇿

Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia

and more 23 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

First Posted Date
2017-09-13
Last Posted Date
2024-10-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
410
Registration Number
NCT03281369
Locations
🇺🇸

Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States

🇺🇸

Tennessee Oncology - Nashville, Nashville, Tennessee, United States

🇦🇺

Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia

and more 33 locations

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

First Posted Date
2017-09-06
Last Posted Date
2022-09-21
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
446
Registration Number
NCT03273153
Locations
🇺🇸

USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States

🇺🇸

Florida Cancer Specialists, West Palm Beach, Florida, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 118 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy